The DHSC has updated prescribers on the ongoing shortage of raniditine following withdrawal of supplies last year over concerns of possible contamination with N-nitrosodimethylamine (NDMA).
Ranitidine injection is expected to be unavailable from the end of May, according to the DHSC. The film-coated tablets, effervescent tablets and oral solution are already out of stock.
The DHSC says manufacturers are unable to advise on resupply dates for any ranitidine products because of ongoing testing required by the MHRA and EMA. Until these investigations are complete, no further supplies of the drug can be manufactured.
Oral and injectable
Of the three suppliers of IV ranitidine, Alliance Healthcare and Advanz Pharma have advised they have limited stocks available and they anticipate being out of stock by the end of May 2020. GSK, manufacturer of Zantac 50mg/2ml injection, is also experiencing a long-term out of stock situation.
Advice has been reissued for switching to alternative injectable products. The DHSC says there are currently sufficient stocks of alternative IV PPIs to support increased demand.
Advice on switching oral preparations also remains the same as previously published. The DHSC says supplies of alternative PPIs are 'readily available' although stocks of some H2 receptor antagonists are limited so these should only be prescribed if PPIs are unsuitable.
The latest supply information for alternative H2 receptor antagonists can be found on the MIMS drug shortages tracker.